Nivolumab may induce successful depletion of HIV reservoir

December 4, 2017

(HealthDay)—Nivolumab treatment for non-small-cell lung cancer may induce successful depletion of HIV reservoir, according to a letter to the editor published online Dec. 1 in the Annals of Oncology.

Amélie Guihot, M.D., from the Hôpital Pitié Salpêtrière in Paris, and colleagues describe the case of a 51-year-old smoker, who had HIV infection since 1995, and was diagnosed with stage IIIa in May 2015. Less than six months after the end of , relapse occurred and he was treated with nivolumab as a second-line agent in December 2016. The pre-treatment plasma HIV load was undetectable under emtricitabine, tenofovir, and dolutegravir.

The authors observed a progressive and modest increase in the plasma HIV load up to 101 copies/mL at 45 days, followed by a decrease to 31 copies/mL at day 120. A slight increase in T cell activation was seen between day 14 and 45, while decreases were seen in PD1 + CD4 and CD8 T at day 30. A marked increase was seen in the frequencies of HIV RT− and Nef-specific CD8 T cells from day 30 to 120. A drastic and persistent decrease was seen in the cell-associated HIV-DNA from 369 at day 0 to 30 copies per 106 cells at day 120.

"This first report of a successful depletion of the HIV reservoirs opens new therapeutic perspectives towards an HIV cure," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient

More information: Abstract/Full Text

Related Stories

Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient

November 30, 2017
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.

Measuring plasma PCSK9 may ID resistance to PCSK9 inhibitors

November 29, 2017
(HealthDay)—Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) may help assess apparent resistance to PCSK9 inhibitors, according to a research letter published online Nov. 28 in the Annals of Internal ...

White blood cell count predicts response to lung cancer immunotherapy

May 4, 2017
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).

Promising immunotherapy drug now available for some lung cancer patients in England

September 21, 2017
Some lung cancer patients in England can now be offered a potentially life-extending immunotherapy drug.

Two-drug immunotherapy deemed safe for lung cancer patients, study shows

June 2, 2016
Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that ...

Checkpoint inhibitors no less safe with radiation

September 29, 2017
(HealthDay)—Immune-related adverse events (IRAEs), including pneumonitis, are not more common in patients with metastatic lung cancer who receive both immune checkpoint inhibitors (CPIs) and thoracic radiotherapy (TRT), ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.